BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 21148155)

  • 1. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis.
    Papsdorf V; Horneff G
    Rheumatology (Oxford); 2011 Jan; 50(1):214-21. PubMed ID: 21148155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.
    Horneff G; De Bock F; Foeldvari I; Girschick HJ; Michels H; Moebius D; Schmeling H;
    Ann Rheum Dis; 2009 Apr; 68(4):519-25. PubMed ID: 18413440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept.
    Borte S; Liebert UG; Borte M; Sack U
    Rheumatology (Oxford); 2009 Feb; 48(2):144-8. PubMed ID: 19074187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy.
    van der Heijde D; Burmester G; Melo-Gomes J; Codreanu C; Mola EM; Pedersen R; Freundlich B; Chang DJ;
    Ann Rheum Dis; 2008 Feb; 67(2):182-8. PubMed ID: 17728331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis.
    Horneff G; Ebert A; Fitter S; Minden K; Foeldvari I; Kümmerle-Deschner J; Thon A; Girschick HJ; Weller F; Huppertz HI
    Rheumatology (Oxford); 2009 Aug; 48(8):916-9. PubMed ID: 19483091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
    Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P
    Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum osteopontin as a predictive marker of responsiveness to methotrexate in juvenile idiopathic arthritis.
    Masi L; Ricci L; Zulian F; Del Monte F; Simonini G; Capannini S; De Martino M; Brandi ML; Falcini F
    J Rheumatol; 2009 Oct; 36(10):2308-13. PubMed ID: 19684155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The German etanercept registry for treatment of juvenile idiopathic arthritis.
    Horneff G; Schmeling H; Biedermann T; Foeldvari I; Ganser G; Girschick HJ; Hospach T; Huppertz HI; Keitzer R; Küster RM; Michels H; Moebius D; Rogalski B; Thon A;
    Ann Rheum Dis; 2004 Dec; 63(12):1638-44. PubMed ID: 15115709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register.
    Prince FH; Twilt M; ten Cate R; van Rossum MA; Armbrust W; Hoppenreijs EP; van Santen-Hoeufft M; Koopman-Keemink Y; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2009 May; 68(5):635-41. PubMed ID: 18413443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.
    Quartier P; Taupin P; Bourdeaut F; Lemelle I; Pillet P; Bost M; Sibilia J; Koné-Paut I; Gandon-Laloum S; LeBideau M; Bader-Meunier B; Mouy R; Debré M; Landais P; Prieur AM
    Arthritis Rheum; 2003 Apr; 48(4):1093-101. PubMed ID: 12687553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis.
    Lovell DJ; Reiff A; Jones OY; Schneider R; Nocton J; Stein LD; Gedalia A; Ilowite NT; Wallace CA; Whitmore JB; White B; Giannini EH;
    Arthritis Rheum; 2006 Jun; 54(6):1987-94. PubMed ID: 16732547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents.
    Russo RA; Katsicas MM
    J Rheumatol; 2009 May; 36(5):1078-82. PubMed ID: 19435972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
    Lurati A; Pontikaki I; Teruzzi B; Desiati F; Gerloni V; Gattinara M; Cimaz R; Fantini F
    Arthritis Rheum; 2006 May; 54(5):1602-7. PubMed ID: 16646003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
    Gerloni V; Pontikaki I; Gattinara M; Fantini F
    Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes after withdrawal of anti-tumor necrosis factor α therapy in patients with juvenile idiopathic arthritis: a twelve-year experience.
    Baszis K; Garbutt J; Toib D; Mao J; King A; White A; French A
    Arthritis Rheum; 2011 Oct; 63(10):3163-8. PubMed ID: 21702011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed clinical response in patients with juvenile idiopathic arthritis treated with etanercept.
    Otten MH; Prince FH; Twilt M; van Rossum MA; Armbrust W; Hoppenreijs EP; Kamphuis S; Koopman-Keemink Y; Wulffraat NM; Gorter SL; Ten Cate R; van Suijlekom-Smit LW
    J Rheumatol; 2010 Mar; 37(3):665-7. PubMed ID: 20080910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept.
    Solari N; Palmisani E; Consolaro A; Pistorio A; Viola S; Buoncompagni A; Gattorno M; Picco P; Ruperto N; Malattia C; Martini A; Ravelli A
    J Rheumatol; 2013 Feb; 40(2):192-200. PubMed ID: 23204218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relation of interleukin-6, TNF-alpha and interleukin-1alpha with disease activity and severity in juvenile idiopathic arthritis patients.
    Spîrchez M; Samaşca G; Iancu M; Bolba C; Miu N
    Clin Lab; 2012; 58(3-4):253-60. PubMed ID: 22582498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etanercept improves linear growth and bone mass acquisition in MTX-resistant polyarticular-course juvenile idiopathic arthritis.
    Billiau AD; Loop M; Le PQ; Berthet F; Philippet P; Kasran A; Wouters CH
    Rheumatology (Oxford); 2010 Aug; 49(8):1550-8. PubMed ID: 20444859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial.
    van der Heijde D; Klareskog L; Singh A; Tornero J; Melo-Gomes J; Codreanu C; Pedersen R; Freundlich B; Fatenejad S
    Ann Rheum Dis; 2006 Mar; 65(3):328-34. PubMed ID: 16079172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.